MCK 10-K Annual Reports

McKesson Corporation's fiscal year 2025 performance demonstrated robust revenue growth, up 16% year-over-year, driven primarily by its U.S. Pharmaceutical segment, which saw increased volumes from retail national accounts and growth in specialty pharmaceuticals. The company also reported a significant increase in diluted earnings per share from continuing operations to $25.72, up from $22.39 in the prior year. Key financial events impacting the year included a $667 million charge related to the sale of its Canadian retail businesses and $298 million in restructuring charges for enterprise-wide efficiency initiatives. McKesson returned $3.5 billion to shareholders through share repurchases and dividends, underscoring its commitment to capital return. The company is actively managing significant legal and regulatory challenges, particularly those related to opioid litigation, for which it has accrued $6.4 billion in liabilities. While these are ongoing, the company's core pharmaceutical distribution and technology solutions segments appear to be performing well, evidenced by the revenue and EPS growth. Strategic investments in technology and ongoing efforts to drive operational efficiencies are key focus areas for future performance.

McKesson Corporation (MCK) has filed its 10-K for the fiscal year ended March 30, 2024, detailing its performance as a diversified healthcare services leader. The company reported increased revenues, primarily driven by its U.S. Pharmaceutical segment, which benefited from growth in specialty pharmaceuticals and higher volumes. However, diluted earnings per share saw a decrease compared to the prior year, impacted by a significant provision for bad debts related to the bankruptcy of its customer, Rite Aid. Mckesson continues to manage various legal and regulatory matters, including significant opioid-related litigation, which resulted in a substantial charge for the current fiscal year. Despite these challenges, the company returned considerable capital to shareholders through share repurchases and dividends, underscoring its commitment to shareholder value. The company also highlighted its ongoing investments in technology and operational efficiencies across its four main business segments: U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International.

McKesson Corporation's (MCK) 2023 10-K filing highlights a year of strategic divestitures and acquisitions, with a notable focus on exiting European operations while strengthening its Prescription Technology Solutions (RxTS) segment. Revenues saw a 5% increase, primarily driven by growth in the U.S. Pharmaceutical segment, which benefited from market growth, specialty pharmaceuticals, and higher branded drug prices. This top-line expansion was partially offset by divestitures in the International segment and unfavorable foreign currency impacts. Despite revenue growth, gross profit experienced a 6% decrease, mainly due to the European divestitures and foreign currency impacts, though this was partially mitigated by gains in specialty pharmaceuticals and generics within the U.S. Pharmaceutical segment. The company demonstrated strong expense management, with total operating expenses decreasing by 28%, largely due to the prior year's significant remeasurement charges related to European divestitures. Diluted earnings per share from continuing operations saw a substantial increase, primarily attributed to the reduced remeasurement charges compared to the prior year and a lower share count resulting from ongoing share repurchase programs. Key strategic moves included the acquisition of Rx Savings Solutions, LLC, to enhance patient affordability and adherence solutions, and the formation of SCRI Oncology, LLC with HCA Healthcare to advance cancer research. The company also returned significant capital to shareholders through share repurchases and increased its quarterly dividend. Investors should monitor the ongoing opioid litigation, which continues to be a significant contingent liability, although the company has made substantial progress on settlements.

McKesson Corporation's fiscal year 2022 (ending March 31, 2022) was marked by robust revenue growth and a significant recovery from the impacts of the COVID-19 pandemic in the prior year. Total revenues increased by 11% to $264 billion, driven primarily by the U.S. Pharmaceutical segment. The company saw improvements in gross profit, up 8%, bolstered by specialty pharmaceuticals, COVID-19 vaccine distribution, and increased patient visits in primary care. A significant strategic development during the year was the initiation of exits from European businesses, including the sale of UK and Austrian operations and agreements to sell EU businesses. These divestitures are part of a strategy to focus on core healthcare services. While these actions led to substantial charges related to fair value remeasurements, the underlying operational performance of the company remained strong. The company also reported a substantial charge related to its estimated liability for opioid-related claims, a significant ongoing legal matter. Despite these charges, McKesson returned $3.8 billion to shareholders through repurchases and dividends, underscoring a commitment to shareholder returns.

McKesson Corporation's 2021 10-K report highlights a year of revenue growth driven primarily by its U.S. Pharmaceutical segment, which saw a 3% increase to $238.2 billion, largely due to market growth. The company played a significant role in the COVID-19 pandemic response, distributing vaccines and ancillary supplies, which positively impacted its Medical-Surgical Solutions and U.S. Pharmaceutical segments. However, the reported net loss attributable to McKesson Corporation was substantial at $(4.5) billion, primarily due to a significant charge of $8.1 billion related to its estimated liability for opioid-related claims. Despite this, the company returned $1.0 billion to shareholders through stock repurchases and dividends, and its financial condition remained strong with access to liquidity. The company also reorganized its business segments into four reportable divisions: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions.

McKesson Corporation's 2020 10-K filing highlights a year of significant revenue growth, driven primarily by its U.S. Pharmaceutical and Specialty Solutions segment. The company experienced an 8% increase in revenues, reaching $231.1 billion, fueled by market growth, branded pharmaceutical price increases, and increased volumes. Despite revenue growth, gross profit saw a more modest 2% increase, impacted by factors like lower net cash proceeds from antitrust legal settlements and unfavorable foreign currency exchange fluctuations. The company's financial performance was also significantly affected by non-recurring items. These included substantial goodwill impairment charges in previous years, notably impacting the European Pharmaceutical Solutions segment, and more recently, charges related to the remeasurement of assets for a German wholesale business joint venture. Notably, McKesson completed the separation of its investment in Change Healthcare JV, recognizing a significant gain related to this transaction. The company also addressed ongoing opioid-related litigation, recording a substantial charge for a settlement with two Ohio counties. Operationally, McKesson continued to return value to shareholders through share repurchases ($1.9 billion) and dividends ($294 million). The company maintained a strong liquidity position throughout the year, even as it navigated the initial impacts of the COVID-19 pandemic late in the fiscal year, which had a muted financial impact due to its timing. Looking ahead, McKesson faces ongoing risks related to litigation, regulatory changes, competition, and supply chain disruptions, particularly in light of the evolving COVID-19 situation.

McKesson Corporation's (MCK) 10-K filing for the fiscal year ended March 31, 2019, reveals a company navigating a dynamic healthcare landscape. The report highlights the company's core business in pharmaceutical and medical-surgical distribution, alongside its specialty care and technology solutions. While revenues saw an increase, driven by market growth and acquisitions, significant goodwill and asset impairments, particularly in the European segment, impacted profitability. The company also detailed ongoing restructuring initiatives aimed at improving efficiency and cost structures. Investors should note the company's substantial revenue generation but also the substantial goodwill impairments and restructuring charges. Key operational segments include U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company continues to manage risks associated with regulatory changes, pricing pressures, and supply chain complexities, while also actively engaging in share repurchases and dividend payments.

McKesson Corporation's 2018 10-K filing reveals a complex operating landscape, marked by significant goodwill impairments and strategic adjustments. While the company experienced revenue growth in its core Distribution Solutions segment, driven by market expansion and acquisitions, the overall profitability was heavily impacted by substantial non-cash goodwill impairment charges totaling $1.7 billion related to its McKesson Europe and Rexall Health reporting units. These impairments stem from ongoing reimbursement pressures in the UK retail market and challenging dynamics in Canada. The company also divested its Enterprise Information Solutions (EIS) business and contributed a significant portion of its Technology Solutions business to a joint venture, Change Healthcare. Despite these headwinds, McKesson continues to return capital to shareholders through dividends and share repurchases, and it has announced a strategic growth initiative focused on efficiency and innovation. The company's financial health remains robust with significant cash flows from operations, although its significant customer concentration, particularly with CVS Health, and ongoing legal and regulatory scrutiny, especially concerning controlled substance distribution, represent key risks.

McKesson Corporation's 2017 10-K filing reveals a year of significant growth and strategic repositioning. The company, a global leader in healthcare supply chain management, reported a 4% increase in total revenues to $198.5 billion, primarily driven by its Distribution Solutions segment. This growth was supported by market expansion, acquisitions, and increased business with existing customers, despite facing weaker pharmaceutical manufacturer pricing trends. A pivotal development during the fiscal year was the contribution of the majority of McKesson's Technology Solutions businesses to form a joint venture, Change Healthcare. This strategic move, which resulted in a significant pre-tax gain of $3.9 billion, allowed McKesson to focus more intently on its core distribution and specialty care offerings. Despite this large gain, the company also recorded a $290 million goodwill impairment charge related to its EIS business within the Technology Solutions segment, highlighting potential challenges in certain technology areas. McKesson continued its commitment to shareholder returns through share repurchases and dividends, reflecting a focus on enhancing shareholder value while navigating a complex and evolving healthcare landscape.

McKesson Corporation's fiscal year 2016 (ending March 31, 2016) report highlights a period of significant revenue growth, driven primarily by its Distribution Solutions segment, which accounted for approximately 98% of consolidated revenues. The company experienced a 7% increase in total revenues to $190.9 billion, largely due to market growth and expanded business with existing customers in North America, partially offset by unfavorable foreign currency effects and customer losses. Despite revenue growth, the company's gross profit margin saw a slight decrease, mainly attributed to lower sell margins in North America distribution, though this was partially offset by benefits from global procurement arrangements and lower LIFO-related inventory charges. Operating expenses also decreased by 7% year-over-year, benefiting from the sale of certain businesses and lower acquisition-related expenses, but were impacted by restructuring charges. Net income attributable to McKesson Corporation saw a substantial increase of 53% to $2.26 billion, leading to diluted earnings per share of $9.70. The company also continued its commitment to returning capital to shareholders through share repurchases and dividend increases.

McKesson Corporation's 2015 10-K filing reveals a year of significant revenue growth, primarily driven by the acquisition of Celesio AG, which expanded its international footprint. The company's Distribution Solutions segment continues to be the dominant revenue generator, accounting for approximately 98% of total revenues. While the company reported strong revenue increases, it also faced increased operating expenses, partly due to acquisition-related costs and a significant settlement charge for controlled substance distribution claims. Despite these operational costs, McKesson demonstrated a commitment to shareholder returns through continued dividend payments and share repurchases. The company's strategic acquisitions and diverse business offerings position it as a major player in the healthcare distribution and technology sectors. However, investors should remain aware of the competitive landscape and the ongoing regulatory environment within the healthcare industry, which could impact future performance.

McKesson Corporation's 2014 10-K filing highlights a year of significant growth and strategic expansion, largely driven by the acquisition of Celesio AG. The company reported a substantial increase in revenues, reaching $137.6 billion, a 13% rise from the previous year, primarily fueled by its Distribution Solutions segment. This segment, which constitutes the vast majority of McKesson's revenue, saw growth from increased drug utilization, price increases, and the strategic integration of acquired businesses. The company also demonstrated a focus on operational efficiency and technology development within its two core segments: Distribution Solutions and Technology Solutions. While the Distribution Solutions segment continued to dominate revenue, the Technology Solutions segment also showed growth, driven by acquisitions and increased claims processing volume. McKesson continues to navigate a complex and evolving healthcare landscape, facing competition and regulatory scrutiny, but the acquisition of Celesio positions it for expanded global reach and a strengthened market position.

McKesson Corporation's 2013 10-K filing reveals a company with robust operations primarily driven by its Distribution Solutions segment, which accounts for the vast majority of its revenue. The company experienced stable revenues year-over-year, with total revenues reaching $122.455 billion for the fiscal year ending March 31, 2013. This stability was maintained despite some customer losses and price deflation in the generics market, offset by market growth and strategic acquisitions, notably the acquisition of PSS World Medical. Profitability showed strength, with gross profit increasing due to higher generics income, business acquisitions, and improved buy margins, though partially offset by decreased sell margins and product alignment charges. The company also continued its share repurchase program, returning value to shareholders, and maintained a solid financial position with adequate liquidity. Despite facing various legal proceedings and regulatory challenges inherent in the healthcare industry, McKesson demonstrated resilience, with management expressing confidence in its internal controls and future prospects.

McKesson Corporation's 2012 10-K filing details a strong year of revenue growth, primarily driven by its Distribution Solutions segment, which accounted for 97% of total revenues. The company reported a 10% increase in revenue to $122.7 billion, with significant contributions from the acquisition of US Oncology. Gross profit also saw a 10% increase, benefiting from higher generic drug sales and improved margins in both segments. Operating expenses rose due to the US Oncology acquisition and increased employee compensation, but were partly offset by lower litigation charges compared to the prior year. The company demonstrated a commitment to shareholder returns through substantial share repurchases, including a significant Accelerated Share Repurchase (ASR) program. McKesson's financial position remained robust, with strong operating cash flow supporting its activities and a stable debt-to-capital ratio.

McKesson Corporation's 2011 Form 10-K filing highlights its position as a leading healthcare services and information technology company. The report indicates a robust market capitalization, with the aggregate market value of common equity held by non-affiliates exceeding $15.5 billion as of September 2010. This signifies substantial investor confidence and the company's significant presence in the market. The filing structure suggests a comprehensive review of its business operations, risk factors, legal proceedings, financial performance, and corporate governance.

McKesson Corporation's 2010 Form 10-K filing indicates a company with a significant market capitalization, valued at approximately $16.1 billion in September 2009 based on non-affiliate holdings. The company had over 271 million shares of common stock outstanding as of April 30, 2010. As a large accelerated filer, McKesson is subject to rigorous reporting standards, suggesting a well-established and sizable public entity. This filing structure, encompassing detailed sections on business, risk factors, financial performance, and executive matters, provides a comprehensive overview for investors. The report directs investors to specific sections for in-depth analysis, particularly Part II, which includes Management's Discussion and Analysis of Financial Condition and Results of Operations and detailed financial statements. The incorporation by reference of portions of the company's Proxy Statement into Part III further signifies a commitment to transparent disclosure regarding corporate governance, executive compensation, and security ownership, all critical elements for shareholder evaluation.

McKesson Corporation's 2009 Form 10-K report, filed May 4, 2009, covers the fiscal year ending March 30, 2009. The filing indicates McKesson is a large accelerated filer, with a substantial market capitalization of approximately $14.5 billion in September 2008. This report provides a comprehensive overview of the company's business operations, financial performance, risk factors, and management's discussion of results and financial condition. Investors should pay close attention to the detailed business segments, potential risks that could impact future performance, and the financial data presented. The report also incorporates by reference portions of the company's 2009 Proxy Statement, which will likely contain important information regarding corporate governance, executive compensation, and security ownership. The extensive table of contents suggests a thorough review of McKesson's operational and financial landscape for the period.

McKesson Corporation's 2008 Form 10-K report highlights its position as a large accelerated filer, indicating significant market capitalization and operational scale. The company's substantial market value, approximately $16.3 billion based on non-affiliate equity in September 2007, underscores its prominence in the healthcare industry. With over 277 million shares outstanding as of April 2008, McKesson demonstrates a broad shareholder base and active trading on the market.

McKesson Corporation's 2007 10-K filing for the fiscal year ending March 30, 2007, reveals a company demonstrating continued growth and operational performance within the pharmaceutical distribution and healthcare services sectors. The report highlights the company's strategic focus on expanding its market reach and enhancing its service offerings, which are critical for its position as a leading healthcare services provider. Investors should note the company's robust revenue generation and efforts to manage operational complexities, which are key indicators of its financial health and market standing. While the filing details solid financial results, it's important for investors to also consider the inherent risks associated with the pharmaceutical and healthcare industries, as outlined in the Risk Factors section. These can include regulatory changes, competitive pressures, and supply chain disruptions. McKesson's ability to navigate these challenges effectively will be crucial for its sustained success and shareholder value creation. The company's consistent performance suggests a well-managed business, but ongoing vigilance regarding industry dynamics and strategic execution remains paramount for stakeholders.

McKesson Corporation's 2006 10-K filing presents a company operating in the healthcare distribution and information technology sectors. The report covers the fiscal year ending March 30, 2006, detailing the company's business operations, financial performance, and risk factors. Investors should note McKesson's significant market position in pharmaceutical distribution, a segment characterized by high volume and tight margins. The company's strategies likely involve optimizing its supply chain, expanding its customer base, and adapting to the evolving healthcare landscape, including regulatory changes and technological advancements in healthcare IT.

McKesson Corporation's 2005 10-K filing indicates a company operating within the pharmaceutical distribution and healthcare services sector. While the provided excerpt focuses on the structure of the filing rather than detailed financial performance, it outlines the key areas investors would examine. These include the company's business operations, properties, legal proceedings, and market performance, alongside critical financial disclosures and management's analysis of results and financial condition. Investors should pay close attention to the 'Management's Discussion and Analysis of Results of Operations and Financial Condition' and the 'Financial Statements and Supplementary Data' sections for a comprehensive understanding of the company's financial health and strategic direction. Further insights would be gained by reviewing the specific details within these sections, particularly regarding revenue streams, profitability, cash flows, and any significant risks or opportunities identified by management. The filing also touches upon corporate governance and executive compensation, which are important factors for long-term investor confidence and value creation. Given the date of the filing (May 2005), this report reflects the company's performance and market position prior to significant market shifts and regulatory changes that may have occurred since.

McKesson Corporation's 2004 Form 10-K report details a significant year for the company, characterized by robust revenue growth and strategic positioning within the healthcare distribution sector. The company appears to be leveraging its scale and operational efficiency to navigate a dynamic market. Investors should note the company's primary business segments, which are crucial to understanding its revenue streams and competitive advantages. The report also sheds light on the company's financial health, operational strategies, and risk management practices, providing a comprehensive overview of its performance and outlook.

McKesson Corporation's 2003 10-K filing reveals a company heavily reliant on its Pharmaceutical Solutions segment, which constitutes 93% of its total revenue. This segment is a leading distributor of drugs and health products in North America and offers various patient and payor services. The company operates through three main segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Information Solutions, with a strategy focused on building strong customer relationships to drive sales of additional products and services. Despite its established market position, McKesson is navigating significant legal challenges, most notably a class-action lawsuit related to accounting irregularities in its former Information Solutions segment (formerly HBO&Company). The company is also subject to other litigation, including product liability claims and environmental matters. While these legal issues present potential risks, the company's robust revenue from its core distribution business suggests underlying operational strength, though investors should remain aware of the financial implications of these ongoing legal battles.

McKesson Corporation's 2002 10-K filing reveals a company focused on its three core segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Information Solutions. The Pharmaceutical Solutions segment is the dominant revenue driver, accounting for 93% of total revenues, and demonstrated significant growth in the fiscal year ended March 31, 2002. Despite the overall revenue increase, the company faced substantial legal challenges stemming from past accounting improprieties related to the HBOC acquisition, with numerous securities litigation cases ongoing. Management highlighted efforts to manage expenses and improve operational efficiency across its segments.

McKesson HBOC, Inc. (now McKesson Corporation) in its 2001 10-K filing presents a robust picture of its operations, primarily driven by its Health Care Supply Management segment, which generated over 96% of its $42.0 billion in sales for fiscal year 2001. This segment is a leading distributor of pharmaceuticals and medical-surgical supplies across North America, serving diverse customer bases including retail pharmacies, hospitals, and alternate care sites. The company leverages advanced logistics, information technology, and a network of distribution centers to maintain a competitive edge. The Health Care Information Technology segment, while smaller, contributes significantly through a wide array of software solutions and services for providers and payors, aiming to improve patient care, financial management, and operational efficiency. The company demonstrates a commitment to innovation and product development in this segment, evidenced by substantial R&D expenditures. However, the IT segment also faces significant litigation stemming from past accounting irregularities related to prior HBOC acquisitions, with a substantial number of lawsuits filed and ongoing investigations by regulatory bodies.

McKesson Corporation's 10-K filing amendment from October 1999 provides an update on its financial performance and business operations for the period ending March 30, 1999. The filing primarily serves to amend previous disclosures, indicating a need for clarification or correction of information previously submitted. Investors should note that this filing reflects a period where McKesson was a major distributor of pharmaceuticals and healthcare products, a sector with ongoing regulatory and market dynamics.

McKesson Corporation's 10-K filing for the period ending March 30, 1997, reveals a company engaged in the distribution of pharmaceuticals and health services. The filing indicates McKesson's significant market presence and its role in the healthcare supply chain, serving a diverse customer base including pharmacies, hospitals, and other healthcare providers. Investors can infer a business model focused on efficiency, logistics, and a broad product portfolio within the essential healthcare sector. Key areas of interest for investors from this filing would include the company's revenue streams, operational scale, and any disclosed strategic initiatives or challenges facing the business in the dynamic healthcare market of the mid-1990s. The report provides a snapshot of McKesson's financial health and operational footprint prior to significant industry shifts, making it a valuable historical document for understanding the company's evolution.

This filing represents an amendment to McKesson Corp's 10-K annual report for the period ending March 30, 1996, filed on February 12, 1997. As an amendment, it primarily serves to correct or supplement information previously submitted, rather than presenting entirely new financial data. Investors should review the specific changes and their implications on the company's reported financial position and performance for that fiscal year. The context of this filing is historical, offering a look back at McKesson's operations and disclosures from the mid-1990s, a period of significant evolution in the pharmaceutical and healthcare distribution industry.

McKesson Corporation's 1996 10-K filing covers the fiscal year ending March 30, 1996. As a major distributor of pharmaceuticals and health care products, McKesson's performance is closely tied to the healthcare industry's dynamics. This report provides a snapshot of the company's financial position and operational highlights during a period of significant growth and evolution in healthcare services and technology. Investors can gain insights into McKesson's strategic direction, its market share in key segments, and its approach to managing a complex supply chain. The filing would typically detail revenue streams, product lines, any significant acquisitions or divestitures, and the regulatory environment impacting its operations. Understanding these elements is crucial for assessing the company's stability, growth potential, and overall investment attractiveness in the mid-1990s healthcare landscape.